ODC1 and neoplasm: Further studies are needed to elucidate the specific domains of FATS associated with ODC regulation and to understand how the pharmacological inhibition of this pathway sensitizes NSCLC tumours to FATS therapy, which represents a potential therapeutic approach for NSCLC patients.